| Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human DK Shah, AM Betts Journal of pharmacokinetics and pharmacodynamics 39, 67-86, 2012 | 378 | 2012 |
| Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human DK Shah, AM Betts MAbs 5 (2), 297-305, 2013 | 205 | 2013 |
| Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin DK Shah, N Haddish-Berhane, A Betts Journal of pharmacokinetics and pharmacodynamics 39, 643-659, 2012 | 158 | 2012 |
| A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions M Damelin, A Bankovich, J Bernstein, J Lucas, L Chen, S Williams, A Park, ... Science translational medicine 9 (372), eaag2611, 2017 | 130 | 2017 |
| The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis AM Betts, TH Clark, J Yang, JL Treadway, M Li, MA Giovanelli, Y Abdiche, ... Journal of Pharmacology and Experimental Therapeutics 333 (1), 2-13, 2010 | 115 | 2010 |
| On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach N Haddish-Berhane, DK Shah, D Ma, M Leal, HP Gerber, P Sapra, ... Journal of pharmacokinetics and pharmacodynamics 40, 557-571, 2013 | 75 | 2013 |
| Determination of cellular processing rates for a trastuzumab-maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design KF Maass, C Kulkarni, AM Betts, KD Wittrup The AAPS journal 18, 635-646, 2016 | 71 | 2016 |
| Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus … A Betts, A Keunecke, TJ van Steeg, PH van der Graaf, LB Avery, H Jones, ... MAbs 10 (5), 751-764, 2018 | 60 | 2018 |
| A translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-cadherin LP DART® A Betts, N Haddish-Berhane, DK Shah, PH van der Graaf, F Barletta, ... The AAPS journal 21, 1-16, 2019 | 57 | 2019 |
| A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate DK Shah, LE King, X Han, JA Wentland, Y Zhang, J Lucas, ... The AAPS journal 16, 452-463, 2014 | 55 | 2014 |
| Preclinical to clinical translation of antibody-drug conjugates using PK/PD modeling: a retrospective analysis of inotuzumab ozogamicin AM Betts, N Haddish-Berhane, J Tolsma, P Jasper, LE King, Y Sun, ... The AAPS journal 18, 1101-1116, 2016 | 53 | 2016 |
| Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition AP Singh, W Krzyzanski, SW Martin, G Weber, A Betts, A Ahmad, ... The AAPS journal 17, 389-399, 2015 | 48 | 2015 |
| Evolution of antibody-drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of trastuzumab-emtansine (T-DM1) AP Singh, KF Maass, AM Betts, KD Wittrup, C Kulkarni, LE King, A Khot, ... The AAPS journal 18, 861-875, 2016 | 46 | 2016 |
| The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671 K Beaumont, A Harper, DA Smith, J Bennett European journal of pharmaceutical sciences 12 (1), 41-50, 2000 | 42 | 2000 |
| Mechanistic projection of first‐in‐human dose for bispecific immunomodulatory P‐Cadherin LP‐DART: an integrated PK/PD modeling approach X Chen, N Haddish‐Berhane, P Moore, T Clark, Y Yang, H Li, D Xuan, ... Clinical Pharmacology & Therapeutics 100 (3), 232-241, 2016 | 40 | 2016 |
| Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology A Betts, PH van der Graaf Clinical Pharmacology & Therapeutics 108 (3), 528-541, 2020 | 37 | 2020 |
| Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody–drug conjugates P Sapra, A Betts, J Boni Expert review of clinical pharmacology 6 (5), 541-555, 2013 | 36 | 2013 |
| A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data HM Jones, Z Zhang, P Jasper, H Luo, LB Avery, LE King, H Neubert, ... CPT: Pharmacometrics & Systems Pharmacology 8 (10), 738-747, 2019 | 35 | 2019 |
| Nonlinear oral pharmacokinetics of the α-antagonist 4-amino-5-(4-fluorophenyl)-6, 7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1, 4-diazepin-1-yl] quinoline in humans: Use of … A Harrison, A Betts, K Fenner, K Beaumont, A Edgington, S Roffey, ... Drug metabolism and disposition 32 (2), 197-204, 2004 | 23 | 2004 |
| In vitro and in vivo SAR of pyrido [3, 4-d] pyramid-4-ylamine based mGluR1 antagonists SJ Mantell, KR Gibson, SA Osborne, GN Maw, H Rees, PG Dodd, ... Bioorganic & medicinal chemistry letters 19 (8), 2190-2194, 2009 | 20 | 2009 |
